BMOV

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329639

CAS#: 38213-69-3

Description: BMOV, also known as Bis(maltolato)oxovanadium(IV) is a Potent insulin mimetic. Bis(maltolato)oxovanadium(IV) normalizes glucose and lipid values and restores food and fluid intake to control levels in diabetic rats without increasing insulin levels (0.37 mmol/kg). It attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Its mechanism of action includes inhibition of PTP1B as well as other tyrosine phosphatases. The drug is nontoxic in vitro at useful concentrations and displays no signs of toxicity in mice at high oral doses.


Chemical Structure

img
BMOV
CAS# 38213-69-3

Theoretical Analysis

MedKoo Cat#: 329639
Name: BMOV
CAS#: 38213-69-3
Chemical Formula: C12H10O7V
Exact Mass: 316.99
Molecular Weight: 317.147
Elemental Analysis: C, 45.45; H, 3.18; O, 35.31; V, 16.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Bis(maltolato)oxovanadium(IV), BMOV

IUPAC/Chemical Name: 2-methyl-3-((((2-methyl-4-oxo-4H-pyran-3-yl)oxy)(oxo)vanadio)oxy)-4H-pyran-4-one

InChi Key: XUOLEICXAPEOSI-UHFFFAOYSA-L

InChi Code: InChI=1S/2C6H6O3.O.V/c2*1-4-6(8)5(7)2-3-9-4;;/h2*2-3,8H,1H3;;/q;;;+2/p-2

SMILES Code: O=C1C(O[V](OC2=C(C)OC=CC2=O)=O)=C(C)OC=C1

Appearance: Black solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 317.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Willsky GR, Goldfine AB, Kostyniak PJ, McNeill JH, Yang LQ, Khan HR, Crans DC. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV). J Inorg Biochem. 2001 May;85(1):33-42. PubMed PMID: 11377693.

2: Liu JC, Yu Y, Wang G, Wang K, Yang XG. Bis(acetylacetonato)-oxovanadium(iv), bis(maltolato)-oxovanadium(iv) and sodium metavanadate induce antilipolytic effects by regulating hormone-sensitive lipase and perilipin via activation of Akt. Metallomics. 2013 Jun;5(7):813-20. doi: 10.1039/c3mt00001j. PubMed PMID: 23576171.

3: Sánchez-González C, Rivas-García L, López-Chaves C, Rodríguez-Nogales A, Algieri F, Gálvez J, Gómez-Aracena J, Vera-Ramírez L, Montes-Bayon M, Sanz-Medel A, Llopis J. Exposure to bis(maltolato)oxovanadium(IV) increases levels of hepcidin mRNA and impairs the homeostasis of iron but not that of manganese. Food Chem Toxicol. 2014 Nov;73:113-8. doi: 10.1016/j.fct.2014.08.011. Epub 2014 Aug 25. PubMed PMID: 25168077.

4: Jindal S, Singh M, Balakumar P. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol. 2008 Aug 29;128(3):383-91. Epub 2007 Jul 20. PubMed PMID: 17658639.

5: Yuen VG, Bhanot S, Battell ML, Orvig C, McNeill JH. Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats. Can J Physiol Pharmacol. 2003 Nov;81(11):1049-55. PubMed PMID: 14719040.

6: Shukla R, Barve V, Padhye S, Bhonde R. Synthesis, structural properties and insulin-enhancing potential of bis(quercetinato)oxovanadium(IV) conjugate. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4961-5. PubMed PMID: 15341960.

7: Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, Genbauffe F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorg Biochem. 2003 Aug 1;96(2-3):321-30. PubMed PMID: 12888267.

8: Parajón-Costa BS, Baran EJ. Vibrational spectra of bis(maltolato)oxovanadium(IV): a potent insulin mimetic agent. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Jan;78(1):133-5. doi: 10.1016/j.saa.2010.09.010. Epub 2010 Sep 17. PubMed PMID: 20934377.

9: Sánchez-González C, López-Chaves C, Trenzado CE, Aranda P, López-Jurado M, Gómez-Aracena J, Montes-Bayón M, Sanz-Medel A, Llopis J. Changes in iron metabolism and oxidative status in STZ-induced diabetic rats treated with bis(maltolato) oxovanadium (IV) as an antidiabetic agent. ScientificWorldJournal. 2014 Jan 5;2014:706074. doi: 10.1155/2014/706074. eCollection 2014. PubMed PMID: 24511298; PubMed Central PMCID: PMC3913100.

10: Sanna D, Bíró L, Buglyó P, Micera G, Garribba E. Biotransformation of BMOV in the presence of blood serum proteins. Metallomics. 2012 Jan;4(1):33-6. doi: 10.1039/c1mt00161b. Epub 2011 Nov 17. PubMed PMID: 22094980.

11: Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can J Physiol Pharmacol. 1996 Sep;74(9):1001-9. PubMed PMID: 8960391.

12: Wei YB, Yang XD. Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex. Biometals. 2012 Dec;25(6):1261-8. doi: 10.1007/s10534-012-9587-x. Epub 2012 Sep 27. PubMed PMID: 23015214.

13: Sanchez-Gonzalez C, Bermudez-Peña C, Guerrero-Romero F, Trenzado CE, Montes-Bayon M, Sanz-Medel A, Llopis J. Effect of bis(maltolato)oxovanadium (IV) (BMOV) on selenium nutritional status in diabetic streptozotocin rats. Br J Nutr. 2012 Sep;108(5):893-9. doi: 10.1017/S0007114511006131. Epub 2011 Nov 16. PubMed PMID: 22085676.

14: Mustafi D, Makinen MW. Structure and conformation of bis(acetylacetonato)oxovanadium(IV) and bis(maltolato)oxovanadium(IV) in solution determined by electron nuclear double resonance spectroscopy. Inorg Chem. 2005 Aug 8;44(16):5580-90. PubMed PMID: 16060607.

15: Winter PW, Al-Qatati A, Wolf-Ringwall AL, Schoeberl S, Chatterjee PB, Barisas BG, Roess DA, Crans DC. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains. Dalton Trans. 2012 Jun 7;41(21):6419-30. doi: 10.1039/c2dt30521f. Epub 2012 Apr 30. PubMed PMID: 22569684.

16: Nischwitz V, Davies JT, Marshall D, González M, Gómez Ariza JL, Goenaga-Infante H. Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry. Metallomics. 2013 Dec;5(12):1685-97. doi: 10.1039/c3mt00143a. Epub 2013 Oct 18. PubMed PMID: 24136403.

17: Iglesias-González T, Sánchez-González C, Montes-Bayón M, Llopis-González J, Sanz-Medel A. Absorption, transport and insulin-mimetic properties of bis(maltolato)oxovanadium (IV) in streptozotocin-induced hyperglycemic rats by integrated mass spectrometric techniques. Anal Bioanal Chem. 2012 Jan;402(1):277-85. doi: 10.1007/s00216-011-5286-7. Epub 2011 Aug 13. PubMed PMID: 21842199.

18: Wei Y, Zhang C, Zhao P, Yang X, Wang K. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential. J Inorg Biochem. 2011 Aug;105(8):1081-5. doi: 10.1016/j.jinorgbio.2011.05.008. Epub 2011 May 27. PubMed PMID: 21726771.

19: Vardatsikos G, Mehdi MZ, Srivastava AK. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review). Int J Mol Med. 2009 Sep;24(3):303-9. Review. PubMed PMID: 19639221.

20: Bordbar AK, Creagh AL, Mohammadi F, Haynes CA, Orvig C. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin. J Inorg Biochem. 2009 Apr;103(4):643-7. doi: 10.1016/j.jinorgbio.2008.10.009. Epub 2008 Oct 17. PubMed PMID: 19056126.